





ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) ANTIBODIES IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY IN BRAZILIAN PATIENTS

Cristiane Gruber (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Thelma Larocca Skare (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Ana Paula Beckhauser de Campos (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Vinícius Maestri (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Betania Longo (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Betania Longo (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Juliana Simioni (Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brasil), Renato Mitsunori Nisihara (Universidade Federal do Paraná, Curitiba, PR, Brasil)

BACKGROUND

Background: Anti-CCP (cyclic citrullinated peptide antibody) is considered the hallmark of rheumatoid arthritis. However, these antibodies may be found in other rheumatic diseases such as psoriatic arthritis (PsA).

Aim: This study aims to verify the presence of anti-CCP in a cohort of Brazilian patients with psoriasis with and without arthritis and to analyze if there is any association of anti-CCP (presence) with clinical, serological and treatment data in PsA.

MATERIALS AND METHODS

Methods: This is a cross-sectional study including 91 psoriatic patients (41 with arthritis and 48 without) and 100 controls. Anti-CCP was searched using a commercial ELISA kit (Anti-CCP hs /high sensitive). Data on clinical, serological and treatment profile was obtained retrospectively through chart review. Quality of life and articular inflammatory activity were studied by SF-12 (Short Form Health Survey-12) questionnaire, ASDAS (Ankylosing Spondylitis Disease Activity Score)-ESR (erythrocyte sedimentation rate) and ASDAS-CRP (C reactive protein) respectively. Skin disease was evaluated by PASI (Psoriasis Area Severity Index) and BSA (body surface area). Patients with PsA with and without anti-CCP were compared.

RESULTS

Results: Anti-CCP was present in 1% of controls and in 17.5% in of the psoriasis group (p<0.001). In patients with PsA, they were found in 20.9% and in those without joint disease in 14.5% (p=0.58). Patients with the polyarticular forms of PsA had more anti-CCP positivity than patients with merely skin disease (p= 0.009). Within the group of PsA, those with anti-CCP had more polyarticular forms but no differences were found when quality of life, joint disease activity, degree of skin involvement and treatment requirements were analyzed (all with p=ns).

CONCLUSION

Conclusions: We conclude that the anti-CCP is positive in 17.5% of psoriasis patients and in 20.5 % of the sample with PsA. These autoantibodies are more common in those with the polyarticular forms of arthritis.